0
Tetanus
Muhammad Asim Rana
MBBS, MRCP, SF-CCM, EDIC, FCCP
Department of Critical Care Medicine
King Saud Medical City
Riya...
INTRODUCTION




Nervous system disorder characterized by
muscle spasms
Caused by the toxin-producing anaerobe,
Clostri...
EPIDEMIOLOGY







Developed countries
0.16 cases/million population
Developing countries
approximately 1,000,000 ca...
PATHOGENESIS




Spores of Clostridium tetani, an obligate
anaerobe
After inoculation, C. tetani transforms into a
veget...








After reaching the spinal cord and brain stem via
retrograde axonal transport and binding tightly and
irrevers...


Adrenal malfunction
Lack of neural control of adrenal release of
catecholamines induced by tetanus toxin
produces a hyp...
Remember




Tetanus toxin-induced effects on anterior horns
cells, the brain stem, and autonomic neurons last
are long-...
Predisposing factors







(C. tetani will not grow in healthy tissues, a
convergence of factors must be present in ...
These predisposing factors can also explain
why tetanus can develop in unusual clinical
settings such as in:







...
CLINICAL FEATURES



Incubation period
The incubation period of tetanus can be as short
as one to three days or as long ...
Generalized tetanus



Trismus (lockjaw)
symptoms of autonomic overactivity









irritability
restlessness
s...









Stiff neck
Opisthotonus
Risus sardonicus (sardonic smile)
A board-like rigid abdomen
Periods of apnea due t...


Cephalic tetanus







Neonatal tetanus




injuries to the head or neck
involving initially only cranial nerve...


Severity of illness
the amount of tetanus toxin that reaches the CNS
 to the incubation period of the illness
 the in...
DIFFERENTIAL DIAGNOSIS








Drug-induced dystonias such as those due
to phenothiazines
Trismus due to dental infec...
TREATMENT


The goals of treatment include:
Halting the toxin production
 Neutralization of the unbound toxin
 Control ...
Halting toxin production






Wound management
Antimicrobial therapy
Penicillin G
cefazolin, cefuroxime, or ceftriax...
Neutralization of unbound toxin









Since tetanus toxin is irreversibly bound to tissues, only
unbound toxin is ...


Active immunization
does not confer immunity following recovery from
acute illness
 ALL patients with tetanus should r...
Control of muscle spasms


Generalized muscle spasms are life-threatening




respiratory failure
lead to aspiration
i...
Management of autonomic dysfunction


Beta blockade




Morphine sulphate




(0.5 to 1.0 mg/kg per hour by continuou...
Supportive care




In patients with severe tetanus, prolonged immobility in
the intensive care unit is common
Such pati...
PROGNOSIS




Case-fatality rates for non-neonatal tetanus in
developing countries range from 8 to 50 percent,
while the...
Thank you
Upcoming SlideShare
Loading in...5
×

Tetanus

1,758

Published on

Tetanus, Lock Jaw, Opisthotonus, Tetanus Immunoglobulins, Immunization, Cephalic Tetanus. A much feared topic among residents explained in a simple way.

Published in: Education, Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,758
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
100
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Transcript of "Tetanus"

  1. 1. Tetanus Muhammad Asim Rana MBBS, MRCP, SF-CCM, EDIC, FCCP Department of Critical Care Medicine King Saud Medical City Riyadh, KSA
  2. 2. INTRODUCTION    Nervous system disorder characterized by muscle spasms Caused by the toxin-producing anaerobe, Clostridium tetani. Four clinical patterns Generalized  Local  Cephalic  Neonatal 
  3. 3. EPIDEMIOLOGY      Developed countries 0.16 cases/million population Developing countries approximately 1,000,000 cases of tetanus are estimated to occur worldwide each year with 200,000 to 300,000 deaths Neonatal tetanus, accounted for 180,000 deaths in the year 2002
  4. 4. PATHOGENESIS   Spores of Clostridium tetani, an obligate anaerobe After inoculation, C. tetani transforms into a vegetative rod-shaped bacterium and produce the metalloprotease, tetanospasmin (also known as tetanus toxin).
  5. 5.     After reaching the spinal cord and brain stem via retrograde axonal transport and binding tightly and irreversibly to receptors at these sites tetanus toxin blocks neurotransmission by its cleaving action on membrane proteins involved in neuroexocytosis. The net effect is disinhibition of neurons that modulate excitatory impulses from the motor cortex. Disinhibition of anterior horn cells and autonomic neurons result in    increased muscle tone, painful spasms, and widespread autonomic instability
  6. 6.  Adrenal malfunction Lack of neural control of adrenal release of catecholamines induced by tetanus toxin produces a hypersympathetic state that manifests as  sweating, tachycardia andhypertension.   Muscular rigidity  increase in the resting firing rate of disinhibited motor neurons and lack of inhibition of reflex motor responses to afferent sensory stimuli
  7. 7. Remember   Tetanus toxin-induced effects on anterior horns cells, the brain stem, and autonomic neurons last are long-lasting because recovery requires the growth of new axonal nerve terminals. Tetanolysin is another toxin produced by C. tetani during its early growth phase. It has hemolytic properties and causes membrane damage in other cells, but its role in clinical tetanus is uncertain.
  8. 8. Predisposing factors      (C. tetani will not grow in healthy tissues, a convergence of factors must be present in order for tetanus toxin to be elaborated in the human host.) A penetrating injury resulting in the inoculation of C. tetani spores Co-infection with other bacteria Devitalized tissue A foreign body Localized ischemia
  9. 9. These predisposing factors can also explain why tetanus can develop in unusual clinical settings such as in:       Neonates (due to infection of the umbilical stump) Obstetric patients (after septic abortions) Postsurgical patients (with necrotic infections involving bowel flora) Patients with dental infections Diabetic patients with infected extremity ulcers Patients who inject illicit and/or contaminated drugs
  10. 10. CLINICAL FEATURES   Incubation period The incubation period of tetanus can be as short as one to three days or as long as several months, with a median of 7 to 8 days (range 0 to 112 days in one report)  Inoculation of spores in body locations distant from the central nervous system (eg, the hands or feet) results in a longer incubation period than inoculation close to the central nervous system (eg, the head or neck).
  11. 11. Generalized tetanus   Trismus (lockjaw) symptoms of autonomic overactivity         irritability restlessness sweating tachycardia cardiac arrhythmias labile hypertension hypotension, fever
  12. 12.       Stiff neck Opisthotonus Risus sardonicus (sardonic smile) A board-like rigid abdomen Periods of apnea due to vise-like contraction of the thoracic muscles and/or glottal or pharyngeal muscle contraction Dysphagia
  13. 13.  Cephalic tetanus      Neonatal tetanus   injuries to the head or neck involving initially only cranial nerves may manifest confusing clinical findings including dysphagia, trismus and focal cranial neuropathies facial nerve is most commonly in cephalic tetanus, but involvement of cranial nerves VI, III, IV, and XII may also occur either alone or in combination with others infants within 14 days following birth Local tetanus  tonic and spastic muscle contractions in one extremity or body region
  14. 14.  Severity of illness the amount of tetanus toxin that reaches the CNS  to the incubation period of the illness  the interval from the onset of symptoms to the appearance of spasms  the longer the interval, the milder the clinical features of tetanus. 
  15. 15. DIFFERENTIAL DIAGNOSIS      Drug-induced dystonias such as those due to phenothiazines Trismus due to dental infection Strychnine poisoning due to ingestion of rat poison Malignant neuroleptic syndrome Stiff-man syndrome
  16. 16. TREATMENT  The goals of treatment include: Halting the toxin production  Neutralization of the unbound toxin  Control of muscle spasms  Management of dysautonomia  General supportive management 
  17. 17. Halting toxin production      Wound management Antimicrobial therapy Penicillin G cefazolin, cefuroxime, or ceftriaxone Metronidazole
  18. 18. Neutralization of unbound toxin      Since tetanus toxin is irreversibly bound to tissues, only unbound toxin is available for neutralization. Human tetanus immune globulin (HTIG) should be readily available and is the preparation of choice. A dose of 3000 to 6000 units intramuscularly should be given as soon as the diagnosis of tetanus is considered. Intrathecal administration of tetanus immune globulin is of unproven benefit. Where HTIG is not readily available, equine antitoxin is used in doses of 1500 to 3000 units intramuscularly or intravenously in order to achieve a serum concentration of 0.1 IU/mL The use of pooled intravenous immune globulin (IVIG) has been proposed as a possible alternative to HTIG.
  19. 19.  Active immunization does not confer immunity following recovery from acute illness  ALL patients with tetanus should receive active immunization with a total of three doses of tetanus and diphtheria toxoid spaced at least two weeks apart, commencing immediately upon diagnosis  Subsequent tetanus doses, in the form of Td, should be given at 10-year intervals throughout adulthood. 
  20. 20. Control of muscle spasms  Generalized muscle spasms are life-threatening    respiratory failure lead to aspiration induce generalized exhaustion in the patient. Drugs used to control spasm  Sedatives  Neuromuscular blocking agents  Propofol  Intrathecal Baclofen
  21. 21. Management of autonomic dysfunction  Beta blockade   Morphine sulphate   (0.5 to 1.0 mg/kg per hour by continuous intravenous infusion) is commonly used to control autonomic dysfunction as well as to induce sedation Magnesium sulfate   Labetalol (0.25 to 1.0 mg/min) has frequently been administered because of its dual alpha and beta blocking properties. acts as a presynaptic neuromuscular blocker, blocks catecholamine release from nerves, and reduces receptor responsiveness to catecholamines Other drugs — Other drugs for the treatment of various autonomic events, which have been reported to be useful, are: atropine, clonidine and epidural bupivacaine.
  22. 22. Supportive care   In patients with severe tetanus, prolonged immobility in the intensive care unit is common Such patients are predisposed to      nosocomial infection decubitus ulcers tracheal stenosis gastrointestinal hemorrhage thromboembolic disease.
  23. 23. PROGNOSIS   Case-fatality rates for non-neonatal tetanus in developing countries range from 8 to 50 percent, while the majority of patients with tetanus recover when modern supportive care is available. Neonatal tetanus, once nearly always fatal, now has mortality rates of 10 to 60 percent
  24. 24. Thank you
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×